Placeholder Banner

BIO to redouble efforts to ensure regulatory decision-making is "grounded in scientific and medical expertise"

April 21, 2023
Media Contact
JG

The Supreme Court ruled today that mifepristone will remain accessible during the appeals process of the April 7 Texas ruling that would have declared the Food and Drug Administration (FDA) approval of the drug invalid. 

BIO interim President and CEO, Rachel King, made the following statement: 

“Today’s decision is an important development for patients and for ensuring access to approved medicines. However, we must redouble our efforts to preserve and protect the FDA’s long-standing role as the authority in determining the safety and efficacy of medicines. As legal and medical experts have noted, the courts do not have the expertise or medical training to make these types of complex scientific determinations. At BIO, we will continue to organize and mobilize on behalf of patients and will work tirelessly to ensure that regulatory decision-making is grounded in scientific and medical expertise.”

 

 

 

Discover More
Annual award honors governors for their leadership and commitment to strengthening biotechnology in their state BOSTON (June 17, 2025) – Today, the Biotechnology Innovation Organization (BIO) named Massachusetts Governor Maura Healey…
Industry veteran takes the helm as Dr. Ted Love concludes two-year term marked by strategic growth and transition BOSTON (June 16, 2025) – Today, the Biotechnology Innovation Organization (BIO) announced that Fritz Bittenbender,…
The world’s largest biotech gathering unites 20,000+ leaders to accelerate breakthroughs that heal, protect, and nourish humanityBOSTON (June 16, 2025) The BIO International Convention, the world’s largest and most comprehensive event for…